Hypophosphastasia (HPP): pathogenesis and current treatment options
Hypophosphatasia (HPP) is a rare, inherited, metabolic bone disease characterized by the abnormal development of bones and teeth, due to defective mineralization (1,2). HPP is caused by inactivating mutation(s) within the gene that encodes the tissue-nonspecific isozyme of alkaline phosphatase (TNSA...
Main Author: | LaSalle, Luisa Ellis |
---|---|
Language: | en_US |
Published: |
2018
|
Subjects: | |
Online Access: | https://hdl.handle.net/2144/26886 |
Similar Items
-
Excellent response to asfotase alfa treatment in an adolescent patient with hypophosphatasia
by: Olivia Sarah Strandbech, et al.
Published: (2021-05-01) -
Hipofosfatasia: manifestaciones clínicas, recomendaciones diagnósticas y opciones terapéuticas
by: Gabriel A. Martos-Moreno, et al.
Published: (2018-06-01) -
Case Report: Efficacy of Reduced Doses of Asfotase Alfa Replacement Therapy in an Infant With Hypophosphatasia Who Lacked Severe Clinical Symptoms
by: Yasuko Fujisawa, et al.
Published: (2020-12-01) -
Characterization of tracheobronchomalacia in infants with hypophosphatasia
by: Raja Padidela, et al.
Published: (2020-08-01) -
Clinical application experience of asfotase alfa for a young patient with childhood hypophosphatasia
by: Nataliya Y. Kalinchenko, et al.
Published: (2019-11-01)